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Abstract
Aims: We aimed to assess the impact of B-type natriuretic peptide (BNP) on short-term outcomes in patients 
undergoing transcatheter aortic valve implantation (TAVI).
Methods and results: Of 500 consecutive patients with severe aortic stenosis undergoing TAVI at our insti-
tution, we studied 340 patients who had a BNP assessment prior to TAVI. Patients were divided into tertiles 
- low: BNP ≤201 pg/mL (n=114), mid: BNP 202-595 pg/mL (n=113) and high: BNP ≥596 pg/mL (n=113). 
The primary endpoint was all-cause mortality, cardiac death and major adverse cardiac and cerebrovascular 
events (MACCE; death, major stroke and myocardial infarction) at 30 days. Compared with low tertile, high 
tertile patients were at higher baseline surgical risk (STS score 5.5±3.0 vs. 7.4±4.1, p=0.002). On echocardi-
ography, high tertile patients had smaller valve areas (0.74±0.21 vs. 0.66±0.23 cm2, p=0.008), higher left ven-
tricular (LV) mass indices (123.40±33.66 vs. 168.22±47.96 g/m2, p<0.001) and lower LV ejection fractions 
(61.59±7.18 vs. 42.65±15.41%, p<0.001) as compared with low tertile patients. At 30 days, a significantly 
higher incidence of death (hazard ratio [HR] 7.41, p=0.001) cardiac death (HR 5.82, p=0.006) and MACCE 
(HR 9.04, p<0.001) was observed among high as compared to low tertile patients.
Conclusions: In TAVI patients, higher BNP values at baseline are associated with an increased risk for an 
adverse event periprocedurally and after 30 days, respectively.
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Introduction
Transcatheter aortic valve implantation (TAVI) is a disruptive tech-
nology that has transformed the management of inoperable patients 
with severe symptomatic aortic stenosis1. It is also a viable alterna-
tive to surgical aortic valve replacement (SAVR) among patients at 
high operative risk2. Patient selection is crucial to the success of this 
procedure, and an important component of this process is appropri-
ate risk assessment3. To date, risk algorithms used to predict out-
comes following cardiac surgical procedures have been found 
largely to overestimate the procedural risk of TAVI due to subopti-
mal discrimination and calibration4. Hence, there is an unmet clini-
cal need for variables that may further help to predict patient risk 
accurately. Recent reports have identified a number of baseline var-
iables associated with mortality in patients undergoing TAVI, 
including low body mass5, left ventricular dysfunction6, low-flow, 
low-gradient severe aortic stenosis7, chronic obstructive pulmonary 
disease8 and natriuretic peptides9,10. B-type natriuretic peptide 
(BNP) is released by the heart in response to pressure and volume 
overload11. Among patients undergoing SAVR, BNP was found to 
predict postoperative survival12. Whether or not BNP predicts 
adverse events following TAVI is controversial9,10. Therefore, the 
aim of this study was to determine whether pre-procedural (base-
line; BL) BNP was associated with adverse clinical outcomes in the 
short term following TAVI.
Methods
PATIENT POPULATION
We performed a retrospective analysis of prospectively collected data 
within a dedicated database that included all patients with severe 
native valve aortic stenosis (AS) (indexed AVA [iAVA]) ≤0.6 cm2/m2 
or mean gradient [MG] >40 mmHg), who underwent TAVI at Bern 
University Hospital between August 2007 and April 2012 (n=500). 
All patients were deemed inoperable or at high surgical risk for con-
ventional surgical aortic valve replacement by a multidisciplinary 
team comprising interventional cardiologists and cardiac surgeons. 
Patient flow is shown in Figure 1. Those included in this study were 
all consecutive patients with symptomatic severe native valve AS 
(iAVA ≤0.6 cm2 and/or MG >40 mmHg) undergoing TAVI who had 
a BNP sample taken within seven days prior to TAVI (n=340). 
Patients were subdivided into the following tertiles:
Group 1: low BNP tertile (0-201 pg/mL) (n=114)
Group 2: mid BNP tertile (>201-595 pg/mL) (n=113)
Group 3: high BNP tertile (>595 pg/mL) (n=113)
BNP SAMPLES
Blood samples for BNP were drawn from the antecubital vein into 
chilled EDTA acid test tubes at the time of admission prior to TAVI 
(mean 1.5±1.3 days, range 0-7 days; baseline) and on the day of hos-
pital discharge (6.3±2.8 days post TAVI, range 1-23 days post TAVI). 
BNP levels were determined at baseline (n=340) and discharge 
(n=253) from an EDTA blood sample using a chemiluminescent 
microparticle immunoassay (CMIA) (ARCHITECT BNP assay; 
Abbott Laboratories Diagnostics Division, Abbott Park, IL, USA).
TRANSTHORACIC ECHOCARDIOGRAPHY
Baseline transthoracic two-dimensional echocardiography was per-
formed using commercially available ultrasound systems (Vivid 7 and 
E9; GE Medical Systems, Horten, Norway). Left ventricular (LV) 
assessment was performed as recommended and LV mass calculated 
using the Devereux formula and indexed to body surface area13. 
Mitral, aortic and tricuspid valve regurgitation were evaluated using 
spectral and colour Doppler images and semiquantitatively graded as 
mild, moderate and severe, as recommended14. Aortic valve area was 
assessed using the continuity equation and indexed to the body surface 
area15. Mean valve gradient was measured using continuous wave 
Doppler acquisitions in the apical 5-chamber view15.
TAVI PROCEDURE
TAVI was performed using standard techniques as previously 
described16. Vascular access was transfemoral using the Medtronic 
CoreValve Revalving System (MCRS) (Medtronic, Inc., 
Minneapolis, MN, USA) or the Edwards SAPIEN valve (ESV) 
500
TAVI August 2007 - April 2012
340
BL BNP
253
DC BNP
Included (TAVI for severe native valve aortic stenosis)
All patients with a DC BNP 
had a BL BNP also
Excluded
Excluded (n=160)
— 133 no BNP sampled prior to TAVI
— 17 BNP sampled >7 days prior to TAVI
— 8 valve-in-valve for surgical bioprosthetic dysfunction
— 1 balloon aortic valvuloplasty only
— 1 converted to SAVR prior to valve implantation
Figure 1. Patient flow. TAVI: transcatheter aortic valve implantation; SAVR: surgical aortic valve replacement; BNP: B-type natriuretic 
peptide; BL: baseline; DC: discharge
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(Edwards Lifesciences, Irvine, CA, USA), transapical for the ESV 
or trans-subclavian using the MCRS.
CLINICAL FOLLOW-UP
Adverse events were assessed in hospital, and regular clinical fol-
low-up was performed. All suspected events were adjudicated by 
an unblinded clinical events committee comprising a cardiac sur-
geon and an interventional cardiologist. Baseline clinical and pro-
cedural characteristics and all follow-up data were entered into 
a dedicated database, held at an academic clinical trials unit (CTU 
Bern, Bern University Hospital, Bern, Switzerland) responsible for 
central data audits and maintenance of the database.
DEFINITIONS
Clinical endpoints were defined according to the criteria proposed 
by the Valve Academic Research Consortium (VARC)17.
STUDY ENDPOINTS
The primary endpoint was all-cause mortality, cardiovascular death 
and major adverse cardiovascular and cerebrovascular events 
(MACCE) (composite of all-cause mortality, major stroke and 
myocardial infarction) at 30 days. Secondary endpoints included 
cerebrovascular events (major stroke, minor stroke, transient 
ischaemic attack) and myocardial infarction at 30 days.
STATISTICS
Continuous data are presented as means±standard deviations (SD), 
and categorical variables are depicted as percentages and numbers. 
Categorical variables were compared by means of the chi-square test 
(or Fisher’s test for two-group comparisons), and continuous variables 
were compared using ANOVA (or unpaired t-test for two-group com-
parisons). P-values for a trend across the BNP tertiles were calculated 
using regression (normally distributed variables), logistic regression 
(binomial variables) or multinomial regression (categorical variables 
with three or more categories) analysis. BNP was compared before 
and after TAVI using the paired samples t-test. Time-to-first event data 
were analysed using Cox’s regression testing for a trend across the 
three tertiles, and presented with the Harrell’s concordance statistic 
(c-index). In case two tertiles had no event, only a p-value from 
a Fisher’s exact test was calculated. All p-values and 95% confidence 
intervals (CIs) are two-sided. Two-sided p-values <0.05 were consid-
ered statistically significant. All analyses were performed with 
STATA, version 12 (StataCorp, College Station, TX, USA).
Results
PATIENT CHARACTERISTICS
Baseline characteristics of the patient population are shown in 
Table 1. Mean age was 83.2±4.8 years and there was an observed 
trend towards more males in the high as compared with the mid 
BNP tertile group. As compared with the low BNP tertile group, 
mid and high BNP tertile groups had a significantly higher inci-
dence of previous myocardial infarction, renal failure, moderate 
mitral regurgitation, atrial fibrillation, NYHA Class III/IV symp-
toms and logistic EuroSCORE. The mean (±standard deviation) 
BNP values were 95.6±47.0, 335.2±106.9 and 1,390.7±950.5 pg/
mL in the low, mid and high BNP tertile groups, respectively.
TRANSTHORACIC ECHOCARDIOGRAPHIC CHARACTERISTICS
The transthoracic echocardiographic characteristics of the patient 
population are shown in Table 2. As compared with the low BNP 
tertile group, high BNP tertile patients had significantly smaller 
aortic valve areas, lower LV ejection fractions, higher LV mass 
indices and larger LV cavities.
PROCEDURAL CHARACTERISTICS
Procedural characteristics are shown in Table 3. All patients under-
went TAVI using either the Medtronic CoreValve (n=309 [63%]) or 
Edwards SAPIEN (n=127 [37%]) prosthesis via the transfemoral 
(n=309 [91%]), transapical (n=27 [8%]) or trans-subclavian (n=4 
[1%]) route. High BNP tertile patients were significantly more 
likely to receive the Medtronic CoreValve as compared to low BNP 
tertile patients. In total 29% of patients underwent either staged or 
concomitant revascularisation. Overall device success was 85% 
and absence of device success was mainly due to the presence of 
aortic regurgitation ≥2+ but not because of a failure to implant the 
device successfully.
CHANGE IN BNP BEFORE AND AFTER TAVI
A significant reduction in BNP (baseline 538.94±701.16 vs. dis-
charge 387.89±455.58 pg/mL, p<0.0001) was observed following 
TAVI (Figure 2).
CLINICAL OUTCOMES
Event rates with hazard ratios (HR) for all major clinical endpoints 
at 30 days are provided in Table 4.
0
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Figure 2. Mean decrease in B-type natriuretic peptide (BNP) following 
transcatheter aortic valve implantation among the 253 patients with 
both a baseline and a discharge BNP value available.
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Table 1. Baseline characteristics.
 
All patients
N=340
Aortic stenosis
p-valueLow BNP 
tertile
N=114
Mid BNP 
tertile
N=113
High BNP 
tertile
N=113
Demographics Age (years) 83.2±4.8 82.6±4.9 83.2±4.7 83.6±4.7 0.10
Female gender, n (%) 195 (57%) 69 (61%) 72 (64%) 54 (48%) 0.05
Physical 
dimensions
Height (cm) 164.0±8.2 163.5±8.6 162.3±7.5 166.5±8.1 0.02
Weight (kg) 71.3±13.9 74.2±14.3 71.7±13.5 67.7±13.4 0.002
Body mass index (kg/m²) 26.7±5.1 27.9±5.5 27.5±4.7 24.5±4.3 <0.001
Body surface area (m²) 1.8±0.2 1.8±0.2 1.8±0.2 1.8±0.2 0.17
Cardiac risk 
factors
Diabetes mellitus, n (%) 91 (27%) 34 (30%) 28 (25%) 29 (26%) 0.48
Hypercholesterolaemia, n (%) 207 (61%) 73 (64%) 69 (61%) 65 (58%) 0.32
Hypertension, n (%) 278 (82%) 93 (82%) 95 (84%) 90 (80%) 0.71
Current smoker, n (%) 32 (9%) 8 (7%) 14 (12%) 10 (9%) 0.63
Past medical 
history
Coronary artery disease, n (%) 215 (63%) 71 (62%) 69 (61%) 75 (66%) 0.52
Multivessel disease 138 (41%) 41 (36%) 43 (38%) 54 (48%) 0.07
Previous myocardial infarction, n (%) 53 (16%) 9 (8%) 19 (17%) 25 (22%) 0.004
Previous coronary artery bypass graft, n (%) 51 (15%) 17 (15%) 19 (17%) 15 (13%) 0.73
Previous percutaneous coronary intervention, n (%) 81 (24%) 31 (27%) 20 (18%) 30 (27%) 0.91
Previous stroke, n (%) 28 (8%) 7 (6%) 11 (10%) 10 (9%) 0.46
Peripheral vascular disease, n (%) 52 (15%) 21 (18%) 15 (13%) 16 (14%) 0.37
Chronic obstructive pulmonary disease, n (%) 56 (16%) 25 (22%) 19 (17%) 12 (11%) 0.023
Renal failure (GFR <60 ml/min/1.73 m²) 227 (67%) 60 (54%) 76 (67%) 91 (81%) <0.001
Baseline 
valvular 
disease
Previous valve surgery, n (%) 3 (1%) 2 (2%) 0 (0%) 1 (1%) 0.49
Severity of aortic regurgitation, n (%) 0.29
None 56 (20%) 14 (16%) 26 (27%) 16 (16%)
Mild 199 (70%) 69 (78%) 59 (60%) 71 (71%)
Moderate 31 (11%) 5 (6%) 13 (13%) 13 (13%)
Severe 0 (0%) 0 (0%) 0 (0%) 0 (0%)
Severity of mitral regurgitation, n (%) <0.001
None 17 (5%) 8 (7%) 5 (5%) 4 (4%)
Mild 216 (67%) 87 (79%) 77 (71%) 52 (50%)
Moderate 82 (25%) 15 (14%) 22 (20%) 45 (43%)
Severe 8 (2%) 0 (0%) 4 (4%) 4 (4%)
Baseline 
cardiac rhythm
Atrial fibrillation, n (%) 77 (29%) 12 (13%) 37 (39%) 28 (33%) 0.004
Symptoms Syncope 42 (12%) 15 (13%) 15 (13%) 12 (11%) 0.56
New York Heart Association (NYHA) functional Class 
NYHA III/IV, n (%)
224 (66%) 61 (54%) 77 (68%) 86 (77%) <0.001
Canadian Cardiovascular Society (CCS) angina status 
CCS III/IV, n (%)
40 (12%) 15 (13%) 19 (17%) 6 (5%) 0.07
Risk 
assessment
Logistic EuroSCORE (%) 23.0±13.5 17.0±10.1 21.7±11.8 30.2±14.8 <0.001
STS score (%) 6.3±4.1 5.5±3.0 6.1±4.7 7.4±4.1 0.001
Medications Aspirin, n (%) 220 (65%) 77 (68%) 73 (65%) 70 (62%) 0.38
Clopidogrel, n (%) 64 (19%) 23 (20%) 21 (19%) 20 (18%) 0.63
Oral anticoagulation, n (%) 91 (27%) 23 (20%) 37 (33%) 31 (27%) 0.22
Diuretic, n (%) 238 (70%) 69 (61%) 82 (73%) 87 (77%) 0.007
Beta-blocker, n (%) 180 (53%) 46 (40%) 69 (61%) 65 (58%) 0.010
ACEi/ARB, n (%) 173 (51%) 62 (54%) 58 (51%) 53 (47%) 0.26
Ca channel blocker, n (%) 54 (16%) 26 (23%) 17 (15%) 11 (10%) 0.008
Statin, n (%) 162 (48%) 65 (57%) 48 (42%) 49 (43%) 0.040
Laboratory 
values
Brain natriuretic peptide pg/mL 605.7±787.6 95.6±47.0 335.2±106.9 1,390.7±950.5
Depicted are means ± standard deviations or counts (%). p-values for trend across tertiles using regression (normally distributed variables), logistic 
regression (binary variables) or multinomial regression (categorical variables) analysis. 
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Table 2. Echocardiographic characteristics.
All patients
N=340
Aortic stenosis
p-valueLow BNP tertile
N=114
Mid BNP tertile
N=113
High BNP tertile
N=113
AS severity Aortic valve area 0.69±0.21 0.74±0.21 0.66±0.19 0.66±0.23 0.008
Mean gradient, mmHg 43.41±16.42 44.29±14.27 45.10±16.22 40.97±18.10 0.18
Peak gradient, mmHg 69.86±25.20 71.78±19.20 71.49±25.88 66.96±27.95 0.26
Aortic velocity, m/s 4.00±0.86 4.06±0.78 4.05±0.81 3.92±0.95 0.36
LV 
dimensions
LV mass index 151.60±46.98 123.40±33.66 148.03±44.73 168.22±47.96 <0.001
LV end-systolic diameter 34.59±12.43 26.32±7.73 30.17±6.89 42.51±13.34 <0.001
LV end-diastolic diameter 48.94±9.92 43.31±7.67 46.19±7.71 54.14±10.13 <0.001
LVEF 52.79±14.21 61.59±7.18 54.49±11.52 42.65±15.41 <0.001
Depicted are means ± standard deviations or counts (%). p-values for trend across tertiles using regression analysis.
Table 3. Procedural characteristics.
All patients
N=340
Aortic stenosis
p-valueLow BNP tertile
N=114
Mid BNP tertile
N=113
High BNP tertile
N=113
Access route 0.25
Femoral, n (%) 309 (91%) 105 (92%) 105 (93%) 99 (88%)
Apical, n (%) 27 (8%) 9 (8%) 7 (6%) 11 (10%)
Subclavian, n (%) 4 (1%) 0 (0%) 1 (1%) 3 (3%)
Valve type 0.023
Medtronic CoreValve, n (%) 213 (63%) 62 (54%) 73 (65%) 78 (69%)
Edwards SAPIEN valve, n (%) 127 (37%) 52 (46%) 40 (35%) 35 (31%)
Revascularisation 0.59
No revascularisation, n (%) 241 (71%) 81 (71%) 80 (71%) 80 (71%)
Concomitant PCI, n (%) 64 (19%) 20 (18%) 20 (18%) 24 (21%)
Staged PCI, n (%) 35 (10%) 13 (11%) 13 (12%) 9 (8%)
Procedural specifications 0.80
Device success, n (%) 290 (85%) 100 (88%) 96 (85%) 94 (83%)
No device success: valve in series, n (%) 4 (1%) 1 (1%) 2 (2%) 1 (1%)
No device success: AR >2, n (%) 44 (13%) 12 (11%) 15 (13%) 17 (15%)
No device success: access failure, n (%) 2 (1%) 1 (1%) 0 (0%) 1 (1%)
AR: aortic regurgitation; access failure: failure of deployment or retrieval. Depicted are means ± standard deviations or counts (%). p-values for trend 
across tertiles using logistic regression (valve type), or multinomial regression (the other categorical variables) analysis.
Table 4. Clinical outcomes at 30 days.
30-day follow-up
Aortic stenosis
Mid vs. low
HR (95% CI)
High vs. low
HR (95% CI)
p-value c-indexLow BNP 
tertile
N=114
Mid BNP 
tertile
N=113
High BNP 
tertile
N=113
All-cause death, n (%) 2 (1.8) 1 (0.9) 14 (13.3) 0.50 (0.05-5.52) 7.41 (1.68-32.60) 0.001 0.74
Cardiovascular death, n (%) 2 (1.8) 0 (0.0) 11 (10.8) 5.82 (1.29-26.27) 0.006 0.74
Cerebrovascular events 1 (0.9) 0 (0.0) 9 (8.3) 9.57 (1.21-75.53) 0.010 0.77
Major stroke, n (%) 1 (0.9) 0 (0.0) 8 (7.4) 8.50 (1.06-67.94) 0.015 0.77
Minor stroke, n (%) 0 (0.0) 0 (0.0) 1 (0.9) 0.67
Transient ischaemic attack, n (%) 0 (0.0) 0 (0.0) 0 (0.0)
Myocardial infarction, n (%) 0 (0.0) 1 (0.9) 0 (0.0) 0.67
All-cause death or major stroke, n (%) 2 (1.8) 1 (0.9) 17 (15.9) 0.50 (0.05-5.51) 9.05 (2.09-39.19) <0.001 0.76
All-cause death, major stroke, or MI, n (%) 2 (1.8) 2 (1.8) 17 (15.9) 1.00 (0.14-7.13) 9.04 (2.09-39.14) <0.001 0.75
Depicted are counts (incidence rates % from life-table estimates). Hazard ratios (HR) (95% confidence intervals [CI]) from Cox regressions for 
time-to-event data with p-values for trend across tertiles and Harrell’s concordance c-index, except minor stroke and myocardial infarction with p-value 
from Fisher’s exact test. 
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PRIMARY ENDPOINT AT 30 DAYS
As compared with the low BNP tertile group, high BNP tertile 
patients had a significantly higher incidence of all-cause (hazard 
ratio [HR] 7.41, 95% confidence interval [CI]: 1.68-32.60, p=0.001) 
and cardiac (HR 5.82, 95% CI: 1.29-26.27, p=0.006) mortality at 
30 days. In addition, there was a significantly higher incidence of 
MACCE among high BNP tertile patients as compared to low BNP 
tertile patients (HR 9.04, 95% CI: 2.09-39.14, p<0.001) (Figure 3).
SECONDARY ENDPOINT AT 30 DAYS
High BNP tertile patients had a significantly higher incidence of 
cerebrovascular events (HR 9.57, 95% CI: 1.21-75.53, p=0.01), 
which was largely driven by a higher incidence of major strokes 
(HR 8.50, 95% CI: 1.06-67.94, p=0.015). No significant differ-
ences in the rates of myocardial infarction were observed 
between groups.
Discussion
The main results of this study can be summarised as follows. 
First, baseline BNP levels correlated with patient risk profiles, 
with high tertile BNP patients having a higher incidence of previ-
ous myocardial infarction, moderate mitral regurgitation, atrial 
fibrillation and higher logistic EuroSCORE and STS scores. 
Second, there were significant correlations between baseline BNP 
levels and pre-interventional echocardiographic indices. Patients 
in the high BNP tertile had smaller valve areas, higher LV mass 
indices, larger LV cavity sizes and lower LV ejection fractions on 
echocardiography. Third, a significant reduction in BNP was 
observed following the TAVI procedure. Finally, high BNP tertile 
patients had a significantly higher incidence of death, cardiac 
death, MACCE and cerebrovascular events, including major 
stroke at 30 days.
PREVIOUS STUDIES
To date, there have been just two studies assessing the impact of 
BNP on clinical outcomes after TAVI, and these have shown con-
flicting results9,10. Kefer et al assessed the usefulness of BNP to pre-
dict outcomes among 58 patients undergoing either transfemoral 
(n=34) or transapical (n=24) TAVI with the Edwards SAPIEN valve 
only9. They found that both baseline and 24-hour BNP were inde-
pendent predictors of 30-day survival. The present study corrobo-
rates these findings in a larger population of patients undergoing 
TAVI with both the Edwards SAPIEN valve and the Medtronic 
CoreValve. In addition, we have further extended these findings by 
demonstrating that baseline BNP is also associated with cardiac 
death, MACCE, cerebrovascular events and major stroke. More 
recently, Ben-Dor et al reported that a high BNP level in high-risk 
patients with severe AS was not an independent marker for higher 
mortality but that it did reflect heart failure status10. However, this 
study was limited by the fact that just over one-third of included 
patients (105/289 [36%]) actually underwent TAVI with the 
Edwards SAPIEN valve only, with the rest of the study population 
undergoing either balloon aortic valvuloplasty (n=127), SAVR 
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Figure 3. Kaplan-Meier analysis of death (A), cardiac death (B) and 
major adverse cardiovascular and cerebrovascular events (MACCE; 
composite of death, major stroke, and myocardial infarction) (C) at 
30 days. Low B-type natriuretic peptide (BNP) tertile=0-201 pg/mL; 
mid BNP tertile >201-595 pg/mL; high BNP tertile >595 pg/mL. 
TAVI: transcatheter aortic valve implantation 
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(n=25) or medical therapy (n=32)10. Conversely, all patients in the 
present larger study underwent TAVI with either the Edwards 
SAPIEN or the Medtronic CoreValve.
CLINICAL IMPLICATIONS
BNP is a dynamic biomarker and the value can vary depending on 
the volume status of the patient. Because our findings suggest that 
an elevated BNP is associated with a higher 30-day mortality rate, 
further studies are required to assess whether optimising the vol-
ume status of patients in decompensated heart failure prior to TAVI 
(e.g., using diuretics) may reduce BNP and lead to improved clini-
cal outcomes.
Limitations
First, the present study reports the experience of a single centre 
only. Second, while the time interval between BNP sampling and 
TAVI was ≤7 days (mean 1.5±1.3 days), the interval between bio-
marker sampling and pre-procedural echocardiography was con-
siderably longer (22.2±30.6 days). Third, not all patients 
undergoing TAVI during the study period had a BNP sampled and 
therefore this is not a consecutive patient series. In addition, not 
all patients who had a baseline BNP had a discharge BNP. 
However, all patients who had a discharge BNP had a baseline 
BNP available. Finally, BNP levels could be higher in patients 
with chronic renal impairment11.
Conclusions
Higher BNP values are associated with elevated pre-procedural risk 
and poorer LV function. An elevated baseline BNP is associated 
with a higher incidence of death, cardiac death and MACCE at 
30 days.
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